生物技术公司Precision BioSciences宣布，其用于治疗杜氏肌营养不良症（DMD）的研究性基因疗法Pbgene-Dmd已获得美国食品药品监督管理局（FDA）授予的快速通道资格。
此项认定旨在加速针对严重疾病且具有未竟医疗需求的新药的开发和审评进程。与此同时，公司还计划举办一场专门的投资者活动，重点介绍Pbgene-Dmd项目的进展与前景。
生物技术公司Precision BioSciences宣布，其用于治疗杜氏肌营养不良症（DMD）的研究性基因疗法Pbgene-Dmd已获得美国食品药品监督管理局（FDA）授予的快速通道资格。
此项认定旨在加速针对严重疾病且具有未竟医疗需求的新药的开发和审评进程。与此同时，公司还计划举办一场专门的投资者活动，重点介绍Pbgene-Dmd项目的进展与前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.